| ARLTS1 gene mutations can be considered as a potential predisposing factor in familial hematological malignancies | ARLTS1, potential candidate gene in familial aggregation of hematological malignancies.
Hamadou WS, Besbes S, Mani R, Bourdon V, Ben Youssef Y, Achour B, Regaieg H, Eisinger F, Mari V, Gesta P, Dreyfus H, Bonadona V, Dugast C, Zattara H, Faivre L, Noguchi T, Khélif A, Sobol H, Soua Z. | 04/8/2017 |
| A statistically significant (p = 0.0037) decrease of ARLTS1 expression in prostate cancer cases was detected. | ARLTS1 and prostate cancer risk--analysis of expression and regulation.
Siltanen S, Fischer D, Rantapero T, Laitinen V, Mpindi JP, Kallioniemi O, Wahlfors T, Schleutker J., Free PMC Article | 04/19/2014 |
| the important role of ARLTS1 Cys148Arg variant as a contributor in prostate cancer predisposition | Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.
Siltanen S, Wahlfors T, Schindler M, Saramäki OR, Mpindi JP, Latonen L, Vessella RL, Tammela TL, Kallioniemi O, Visakorpi T, Schleutker J., Free PMC Article | 02/25/2012 |
| A significantly increased risk was observed for young ovarian cancer patients with ARLTS1 Cys148Arg variant. | [Polymorphism of ARLTS1 gene in early-onset ovarian cancer].
Yang XY, Yu H, Peng ZL, Yang XY, Yu H, Peng ZL. | 07/2/2011 |
| The role of the allelic variants in ARLTS1, RAD51 and MDM2 acting in the tumor suppressor, DNA repair and p53 pathways as risk factors for familial breast cancer in 147 patients displaying characteristics of familial disease, was investigated. | ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer.
Akisik E, Yazici H, Dalay N, Akisik E, Yazici H, Dalay N. | 03/26/2011 |
| A novel tumor suppressor gene [ARLTS1 (ADP-ribosylation factor-like tumor suppressor gene 1)]is found to be altered in human carcinogenesis. It is located in Chromosome 13q14.3. | ARLTS1 - a novel tumor suppressor gene.
Yendamuri S, Trapasso F, Calin GA. | 01/25/2010 |
| Data show a significantly increased risk of familial OC for ARLTS1 Cys148Arg variant, which indicate that ARLTS1 may play a role in familial ovarian cancer. | Association of the ARLTS1 variants with familial ovarian cancer risk in China.
Yang XY, Yu H, Xi MR, Yang KX, Pan XL, Hu M, Peng ZL, Yang XY, Yu H, Xi MR, Yang KX, Pan XL, Hu M, Peng ZL. | 01/21/2010 |
| ARLTS1 germline variants are not associated with breast, prostate, and colorectal cancer | ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer.
Siltanen S, Syrjäkoski K, Fagerholm R, Ikonen T, Lipman P, Mallott J, Holli K, Tammela TL, Järvinen HJ, Mecklin JP, Aittomäki K, Blomqvist C, Bailey-Wilson JE, Nevanlinna H, Aaltonen LA, Schleutker J, Vahteristo P, Siltanen S, Syrjäkoski K, Fagerholm R, Ikonen T, Lipman P, Mallott J, Holli K, Tammela TL, Järvinen HJ, Mecklin JP, Aittomäki K, Blomqvist C, Bailey-Wilson JE, Nevanlinna H, Aaltonen LA, Schleutker J, Vahteristo P., Free PMC Articles: PMC3404127, PMC3404127 | 01/21/2010 |
| Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) | ARLTS1 variants and risk of colorectal cancer.
Frank B, Hemminki K, Brenner H, Hoffmeister M, Chang-Claude J, Burwinkel B. | 03/13/2008 |
| Observational study of gene-disease association. (HuGE Navigator) | See all PubMed (11) articlesARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer.
Akisik E, Yazici H, Dalay N, Akisik E, Yazici H, Dalay N. [Polymorphism of ARLTS1 gene in early-onset ovarian cancer].
Yang XY, Yu H, Peng ZL, Yang XY, Yu H, Peng ZL. Association of the ARLTS1 variants with familial ovarian cancer risk in China.
Yang XY, Yu H, Xi MR, Yang KX, Pan XL, Hu M, Peng ZL, Yang XY, Yu H, Xi MR, Yang KX, Pan XL, Hu M, Peng ZL. ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer.
Siltanen S, Syrjäkoski K, Fagerholm R, Ikonen T, Lipman P, Mallott J, Holli K, Tammela TL, Järvinen HJ, Mecklin JP, Aittomäki K, Blomqvist C, Bailey-Wilson JE, Nevanlinna H, Aaltonen LA, Schleutker J, Vahteristo P, Siltanen S, Syrjäkoski K, Fagerholm R, Ikonen T, Lipman P, Mallott J, Holli K, Tammela TL, Järvinen HJ, Mecklin JP, Aittomäki K, Blomqvist C, Bailey-Wilson JE, Nevanlinna H, Aaltonen LA, Schleutker J, Vahteristo P. Association of the ARLTS1 Cys148Arg variant with sporadic and familial colorectal cancer.
Castellví-Bel S, Castells A, de Cid R, Muñoz J, Balaguer F, Gonzalo V, Ruiz-Ponte C, Andreu M, Llor X, Jover R, Bessa X, Xicola RM, Pons E, Alenda C, Payá A, Carracedo A, Piqué JM, Gastrointestinal Oncology Group of the Spanish Gastroenterological Association, Castellví-Bel S, Castells A, de Cid R, Muñoz J, Balaguer F, Gonzalo V, Ruiz-Ponte C, Andreu M, Llor X, Jover R, Bessa X, Xicola RM, Pons E, Alenda C, Payá A, Carracedo A, Piqué JM, Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. No association of ARLTS1 polymorphisms and risk for familial chronic lymphocytic leukaemia.
Ng D, Toure O, Fontaine L, McMaster ML, Goldin LR, Caporaso N, Toro JR, Ng D, Toure O, Fontaine L, McMaster ML, Goldin LR, Caporaso N, Toro JR. ARLTS1 variants and melanoma risk.
Frank B, Meyer P, Boettger MB, Hemminki K, Stapelmann H, Gast A, Schmitt C, Kumar R, Sergi C, Burwinkel B, Frank B, Meyer P, Boettger MB, Hemminki K, Stapelmann H, Gast A, Schmitt C, Kumar R, Sergi C, Burwinkel B. Relationship between ARLTS1 polymorphisms and risk of chronic lymphocytic leukemia.
Sellick GS, Catovsky D, Houlston RS, Sellick GS, Catovsky D, Houlston RS. Cancer Familial Aggregation (CFA) and G446A polymorphism in ARLTS1 gene.
Masojć B, Mierzejewski M, Cybulski C, van de Wetering T, Debniak T, Górski B, Jaworowska E, Tarnowska C, Lenner M, Scott RJ, Lubiński J, Masojć B, Mierzejewski M, Cybulski C, van de Wetering T, Debniak T, Górski B, Jaworowska E, Tarnowska C, Lenner M, Scott RJ, Lubiński J. Association of the ARLTS1 Cys148Arg variant with familial breast cancer risk.
Frank B, Hemminki K, Meindl A, Wappenschmidt B, Klaes R, Schmutzler RK, Untch M, Bugert P, Bartram CR, Burwinkel B. Familial cancer associated with a polymorphism in ARLTS1.
Calin GA, Trapasso F, Shimizu M, Dumitru CD, Yendamuri S, Godwin AK, Ferracin M, Bernardi G, Chatterjee D, Baldassarre G, Rattan S, Alder H, Mabuchi H, Shiraishi T, Hansen LL, Overgaard J, Herlea V, Mauro FR, Dighiero G, Movsas B, Rassenti L, Kipps T, Baffa R, Fusco A, Mori M, Russo G, Liu CG, Neuberg D, Bullrich F, Negrini M, Croce CM, Calin GA, Trapasso F, Shimizu M, Dumitru CD, Yendamuri S, Godwin AK, Ferracin M, Bernardi G, Chatterjee D, Baldassarre G, Rattan S, Alder H, Mabuchi H, Shiraishi T, Hansen LL, Overgaard J, Herlea V, Mauro FR, Dighiero G, Movsas B, Rassenti L, Kipps T, Baffa R, Fusco A, Mori M, Russo G, Liu CG, Neuberg D, Bullrich F, Negrini M, Croce CM. | 03/13/2008 |
| Cysteine148Arginine variant is associated with a moderately increased risk of colorectal cancer, both in sporadic and familial cases. | Association of the ARLTS1 Cys148Arg variant with sporadic and familial colorectal cancer.
Castellví-Bel S, Castells A, de Cid R, Muñoz J, Balaguer F, Gonzalo V, Ruiz-Ponte C, Andreu M, Llor X, Jover R, Bessa X, Xicola RM, Pons E, Alenda C, Payá A, Carracedo A, Piqué JM, Gastrointestinal Oncology Group of the Spanish Gastroenterological Association, Castellví-Bel S, Castells A, de Cid R, Muñoz J, Balaguer F, Gonzalo V, Ruiz-Ponte C, Andreu M, Llor X, Jover R, Bessa X, Xicola RM, Pons E, Alenda C, Payá A, Carracedo A, Piqué JM, Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. | 01/21/2010 |
| 650 transcripts expressed after restoration of ARLTS1 expression were identified in A549 cells, suggesting that pathways involved in cell survival, proliferation, signaling, and development mediate the effects of wild-type ARLTS1 in lung cancer. | Tumor suppressor functions of ARLTS1 in lung cancers.
Yendamuri S, Trapasso F, Ferracin M, Cesari R, Sevignani C, Shimizu M, Rattan S, Kuroki T, Dumon KR, Bullrich F, Liu CG, Negrini M, Williams NN, Kaiser LR, Croce CM, Calin GA. | 01/21/2010 |
| The study does not support the postulate that variants of ARLTS1 influence the risk of chronic lymphocytic leukemia(CLL). | Relationship between ARLTS1 polymorphisms and risk of chronic lymphocytic leukemia.
Sellick GS, Catovsky D, Houlston RS, Sellick GS, Catovsky D, Houlston RS. | 01/21/2010 |
| the G446A in ARLTS1 gene is probably not associated with an increased risk of sporadic breast cancer, prostate cancer, melanoma, thyroid papillary cancer or laryngeal cancer | Cancer Familial Aggregation (CFA) and G446A polymorphism in ARLTS1 gene.
Masojć B, Mierzejewski M, Cybulski C, van de Wetering T, Debniak T, Górski B, Jaworowska E, Tarnowska C, Lenner M, Scott RJ, Lubiński J, Masojć B, Mierzejewski M, Cybulski C, van de Wetering T, Debniak T, Górski B, Jaworowska E, Tarnowska C, Lenner M, Scott RJ, Lubiński J. | 01/21/2010 |
| A genetic variant of ARLTS1 predisposes patients to familial cancer. | Familial cancer associated with a polymorphism in ARLTS1.
Calin GA, Trapasso F, Shimizu M, Dumitru CD, Yendamuri S, Godwin AK, Ferracin M, Bernardi G, Chatterjee D, Baldassarre G, Rattan S, Alder H, Mabuchi H, Shiraishi T, Hansen LL, Overgaard J, Herlea V, Mauro FR, Dighiero G, Movsas B, Rassenti L, Kipps T, Baffa R, Fusco A, Mori M, Russo G, Liu CG, Neuberg D, Bullrich F, Negrini M, Croce CM, Calin GA, Trapasso F, Shimizu M, Dumitru CD, Yendamuri S, Godwin AK, Ferracin M, Bernardi G, Chatterjee D, Baldassarre G, Rattan S, Alder H, Mabuchi H, Shiraishi T, Hansen LL, Overgaard J, Herlea V, Mauro FR, Dighiero G, Movsas B, Rassenti L, Kipps T, Baffa R, Fusco A, Mori M, Russo G, Liu CG, Neuberg D, Bullrich F, Negrini M, Croce CM. | 01/21/2010 |
| we found no association of ARLTS1 polymorphisms and risk for familial chronic lymphocytic leukaemia | No association of ARLTS1 polymorphisms and risk for familial chronic lymphocytic leukaemia.
Ng D, Toure O, Fontaine L, McMaster ML, Goldin LR, Caporaso N, Toro JR, Ng D, Toure O, Fontaine L, McMaster ML, Goldin LR, Caporaso N, Toro JR. | 01/21/2010 |
| While ARLTS1 Trp149Stop did not influence melanoma risk (OR = 0.83, 95% CI = 0.37-1.88, p = 0.65), Cys148Arg revealed a statistically significant association with an increased risk for heterozygous carriers (OR = 1.43, 95% CI = 1.05-1.95, p = 0.02) | ARLTS1 variants and melanoma risk.
Frank B, Meyer P, Boettger MB, Hemminki K, Stapelmann H, Gast A, Schmitt C, Kumar R, Sergi C, Burwinkel B, Frank B, Meyer P, Boettger MB, Hemminki K, Stapelmann H, Gast A, Schmitt C, Kumar R, Sergi C, Burwinkel B. | 01/21/2010 |